In this analysis, we examined whether biomarkers of metabolic dysregulation, measured by pre-diagnostic plasma adiponectin, resistin, leptin and Lp(a), increased the risk of cancer mortality differentially by race in a prospective cohort of Blacks and Whites after adjusting for baseline socio-demographics and other risk factors. The gene discussed is RETN; the disease is cancer.